Roivant Sciences is combining with Montes Archimedes Acquisition Corp (MAAC), a particular purpose acquisition company sponsored by Patient Square Capital. 

Merck & Co. Inc. agreed to acquire privately held VelosBio Inc. for $2.75 billion in cash, in a move that will help strengthen the company’s cancer drug portfolio.

GlaxoSmithKline Chairman Sir Philip Hampton will step down from his role ahead of the company’s plan to split into two separate business units.

Pfizer snapped up a small percentage of Rhythm Pharmaceuticals, which is focused on treating rare genetic disorders that lead to obesity.

Biopharmaceutical company Celgene Corp. will buy a stake in BeiGene Ltd. and help develop and commercialize BeiGene’s investigational treatment for tumor cancers.

Swiss drugmaker Novartis will invest up to an extra $15 million in Gamida Cell, an Israeli developer of stem cell therapies, Gamida said on Sunday.   Novartis last year invested $35 million in the company for a 15 percent stake, in a deal that could reach $600 million if Novartis exercises a buyout option that […]

Transaction underscores Teva’s “personalized-medicine” approach to treatment optimization across a spectrum of specialty and generics development programs and lifecycle management initiatives Teva gains exclusive rights to Immuneering’s cutting-edge analytics to advance treatments for diseases of the CNS   JERUSALEM & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and privately-held Immuneering Corporation today […]

Mereo BioPharma Group Ltd (“Mereo”), a recently-formed specialty biopharmaceutical company, announces that it has successfully raised $119m (c. £76.5m), gross, from blue chip institutional investors and simultaneously acquired a portfolio of three innovative clinical-stage development programs from Novartis Pharmaceuticals. Novartis, through the shares issued in consideration for the acquisition of products, will also hold an […]